2023 CMHC Fellows Post-Survey: Women's Health Masterclass

First and Last Name *

Email *

Studies have shown that women have a(n) _________ risk of developing statin intolerance compared to men. *

Higher

Lower

Equal

Which of the following is TRUE about women and ASCVD risk? *

Women are more likely to fill a high statin prescription vs. men

Lipid lowering therapies are less effective in women vs. men

ASCVD is recognized 10 years later on average in women vs. men of same age

Men have a higher prevalence and burden of ASCVD vs. women

All of the following non-statin therapies have shown no difference or improved outcomes in women, EXCEPT: *

According to the 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies, which of the following is an appropriate LDL-C target in a woman with ASCVD, type 2 diabetes and hypertension? *

≥50% LDL-C reduction AND LDL-C <55 mg/dL

≥50% LDL-C reduction OR LDL-C <55 mg/dL

≥50% LDL-C reduction AND LDL-C <70 mg/dL

≥50% LDL-C reduction OR LDL-C <70 mg/dL

≥50% LDL-C reduction AND LDL-C <100 mg/dL

≥50% LDL-C reduction OR LDL-C <100 mg/dL

Which of the following statements is TRUE about the CLEAR Outcomes trial with bempedoic acid? *

It enrolled patients with existing ASCVD

It enrolled patients at-risk for or with existing ASCVD

Significant cardiovascular risk reduction was observed in the primary prevention cohort only

It enrolled patients on high-intensity statin therapy

A 58-year-old female with family history of ASCVD but without a history of an ASCVD event, presents for follow-up. She has experieced adverse events with both atorvastatin and rosuvastatin, and has discontinued statins altogether. Her medical history is relevant for obesity, type 2 diabetes, and hypertension, and her current LDL-C is 110 mg/dL. Which of the following would be most beneficial to help reduce her ASCVD risk? *

Bempedoic acid

Colchicine

Empagliflozin

Simvastatin

Niacin

A 58-year-old woman with a recent myocardial infarction and stent placement to the LAD 6 months ago has been tried multiple statins and has severe myalgias with high intensity and moderate intensity statins. The patient is on a maximally tolerated dose of statin (pravastatin 20 mg daily). Ezetimibe 10 mg is then added and lipid profile reveals: total cholesterol = 261 mg/dL; triglycerides = 150 mg/dL ; HDL = 40 mg/dL; LDL-C = 175 mg/dL; LP(a) = 200 mg/dL. According to the 2022 ACC Expert Decision Pathway on non-statin therapies, which of the following options should you consider next to reduce the risk of future cardiovascular events? *

True or False: according to the 2022 ACC consensus statement on non-statin therapies for LDL-C lowering, inclisiran and a PCSK9 inhibitor can be reasonably combined together in very high-risk patients that need further LDL-C lowering. *

True

False

Participating in this activity increased my knowledge about the management of ASCVD risk in women, including lipid lowering. *

Do you plan to make changes to practice as a result of information received during this meeting? *

Yes

No

If yes, which changes do you plan to make as a result of information provided in this activity? (Select all that appy)

Monitor advances in lipid-lowering therapy and emerging data with newer agents in women

Intensify/add lipid-lowering treatments every 6-12 weeks until LDL-C goal is achieved in all patients including women

Consider more intensive lipid-lowering therapy for very-high risk patients

Monitor patients for potential statin intolerance or non-adherence to other lipid-lowering therapies

Several new drugs or indications have been added for the management of patients with cardiometabolic disease. Which of the following recently-approved drugs or indications are you (or your practice) having the most issues with prior authorization/patient access (select all that apply)? *

For your patients with elevated LDL-C and on maximal statin therapy, what is the most common non-statin agent that you prescribe for further LDL-C lowering? *

Ezetimibe

Bempedoic acid

Bempedoic acid/ezetimibe combination

PCSK9 inhibitor (evolocumab or alirocumab)

Inclisiran

Not applicable to me/currently do not prescribe

Other...

For your patients with elevated LDL-C and on maximal statin therapy, what is the most common non-statin agent that you prescribe for further LDL-C lowering? Other...

PLEASE SHARE 3-5 PERSONAL LEARNINGS FROM ATTENDING THE WOMEN’S CARDIOMETABOLIC HEALTH AND WELLNESS MASTERCLASS.

What do you expect to learn (or hope to achieve) throughout the course of the year from CMHC's Educational Programs and the Fellows Program?

What are some of the current challenges you face as a fellow in trying to take care of patients with cardiometabolic risk factors or cardiometabolic disease?

Please add any other comments:

You are here

2023 CMHC Fellows Post-Survey: Women's Health Masterclass